Slide 1: 2024 Fourth Quarter Results
2024 Fourth Quarter Results February 19, 2025 Proprietary © Gentherm
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for historical information contained herein, statements in this presentation are forward-looking statements that are made by Gentherm Incorporated (the “Company”) pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All sta
Slide 3: Initial Observations
Initial Observations OBSERVATIONS OPPORTUNITIES OUTCOME Customer’s Partner Map Conquests for of Choice Profitable Growth Revenue Growth Implement Business Opportunity to Drive Process Standardization Operational Improvement Margin Expansion and Maximize Utilization Strong Technology Broaden Applicat
Slide 4: Industry Leading Technologies with Broad Market Application
Industry Leading Technologies with Broad Market Application Core Technology Competencies Scalable Technology Platforms THERMAL AIR MOVING PNEUMATIC VALVE MANAGEMENT DEVICES SOLUTIONS SYSTEMS • CCI Portfolio • CCS® Portfolio • Puls.A Pulsating Massage • Fuel Management • Blanketrol® III System • Warm
Slide 5: Increased Adoption of Next Generation Technologies
Increased Adoption of Next Generation Technologies Puls.A Massage CCS® CompactVent ClimateSense® Software Memory Seat ClimateSense® CCS® High- ClimateSense® Module IPS® Power Series CCS® Quiet Blower Global EV Next Gen Control Units Manufacturer CCS® Neck Conditioner CCS® Neck Conditioner ComfortSca
Slide 6: 4Q and FY Highlights
Highlights 02 03 $640M in Automotive Continued strong launch Record revenue and 4Q New Business Awards activity; 18 different vehicles across 12 OEMs profitability for Medical Segment $2.4B in Automotive Record company Adjusted Maintained net leverage ~0.5x FY New Business Awards, led by accelerated
Slide 7: Select Income Statement Data
Select Income Statement Data Three Months Ended December 31 Twelve Months Ended December 31 (Dollars in thousands, except per share data) 2024 2023 2024 2023 Product Revenues $ 352,914 $ 366,933 $ 1,456,124 $ 1,469,076 Automotive 338,834 353,945 1,406,278 1,422,952 Medical 14,080 12,988 49,846 46,12
Slide 8: Select Balance Sheet Data
Select Balance Sheet Data (Dollars in thousands) December 31, 2024 December 31, 2023 Cash and Cash Equivalents $ 134,134 $ 149,673 Total Assets 1,247,556 1,234,371 Debt 220,201 222,838 Current 137 621 Non-Current 220,064 222,217 Revolving LOC Availability 280,000 278,000 Total Liquidity 414,134 427,
Slide 9: 2025 Guidance
2025 Guidance 2025E(1) Comments ~2% growth (ex-fx) in Product Revenues $1.4B – $1.5B declining market Expansion > 50 bps excluding Adjusted EBITDA Margin 12% – 13% footprint actions Adjusted Effective Tax Rate 26% – 29% ~ Flat year-over-year Growth and footprint Capital Expenditures $70M – $80M inve
Slide 10: Appendix
Appendix Proprietary © Gentherm
Slide 11: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the results reported herein in accordance with GAAP, the Company has provided here or may discuss on the related conference call adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”); Adjusted EBITDA margin; adju
Slide 12: Reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin
Reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin Three Months Ended December 31 Twelve Months Ended December 31 (Dollars in thousands) 2024 2023 2024 2023 Net Income $ 15,321 $ 18,087 $ 64,947 $ 40,343 Add Back: Depreciation and Amortization 12,587 12,062 51,329 50,416 Income Tax Expense
Slide 13: Reconciliation of Adjusted EPS
Reconciliation of Adjusted EPS Three Months Ended December 31 Twelve Months Ended December 31 2024 2023 2024 2023 Diluted EPS - As Reported $ 0.49 $ 0.56 $ 2.06 $ 1.22 Non-Cash Purchase Accounting Impacts 0.05 0.05 0.20 0.22 Restructuring Expenses, net 0.02 0.04 0.42 0.14 Unrealized Currency (Gain)